Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. The Motley Fool->. Weve now already seen a 50% correction in the stock price, with shares changing hands around 46 cents per share. The company stated that it will pursue a path to file for full FDA approval of Covaxin. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." A $30 million market capitalization doesnt mean Ocugen has no chance. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. Plus500. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. If were playing that game then Im buying LEAP call options on Apple and Amazon in March. It means that institutional investors focused on the sector largely have passed on the pipeline. Emergency Use . 1125 N. Charles St, Baltimore, MD 21201. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. The Motley Fool has a disclosure policy. That doesnt mean success is guaranteed. By the beginning of March, the stock was still trading at 45 cents as news of the coronavirus spreading in China prompted concerns about a U.S. pandemic. quotes delayed at least 15 minutes, all others at least 20 minutes. However, when that occurred, Ocugen stock lost most of its value. Typically, I care little about financials with biotechs. The Motley Fool->. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. Instead, this appears destined to join the long list of failed biotech startups. Ocugen had to go an unusual route to go public. To make the world smarter, happier, and richer. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. Still, Ocugens balance sheet isnt as dire as its share price might suggest. Biotech companies have emerged from similar levels to become huge winners, as evidenced simply by looking at some of the best biotech stocks for 2019. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. Investing is always a game of balancing risk and reward. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. Maybe OCGN stock will be one of them again. I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. Click here to see what Matt has up his sleeve now. But if they do, Ocugen stock at the least looks like an intriguing bet. To be sure, current cash isnt enough. Even before that point, the most promising candidates generally can find funding. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Create your Watchlist to save your favorite quotes on Nasdaq.com. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company initiated its Phase 3 trial of OCU300 back in July 2018. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. If they invent a miracle treatment for a condition, the money will find its way to the stock. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. The newly renamed Ocugen stock kept declining through year-end, but has managed to stage a bit of a rally in 2020, gaining 15% year-to-date. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Do Not Sell My Personal Information (CA Residents Only). Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. Investors need to understand the risk profile here. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. In 2018, its NeoCart biologic failed to meet the primary endpoint of its own Phase III trial. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. Investors were hopeful that the small drugmaker would be able to win U.S. The stock had gained some traction after they announced the. Long-term debt of $1.6 million is not a back-breaker either. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. The statistics support having long-term exposure to this asset class. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. What should investors do now? Can you feel the ground moving beneath your feet? However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. Conditions have only become worse since that time. Do Not Sell My Personal Information (CA Residents Only). Shares declined 85% in three sessions around the closing of the merger, which also included a 1-for-60 reverse stock split. *ALL INFO ABOUT THE BIKE AND GEAR USED DOWN BELOW**If not listed it's left stock*BIKE: 2018, BMW R NINET SCRAMBLER.EXHAUST: Akrapovic Headers, Uni. Create your Watchlist to save your favorite quotes on Nasdaq.com. Why Everyone Is Investing in 5G All WRONG, Americas #1 Stock Picker Reveals His Next 1,000% Winner, Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company, Radical New Battery Could Dismantle Oil Markets. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Copy and paste multiple symbols separated by spaces. Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. Maybe. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. Honestly, OCGN stock is unlikely to survive. The second is that the balance sheet still needs some help. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. Companies will inevitably be optimistic about their prospects for success (at least publicly). Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. Here are three prudent steps to take. Since its merger, Ocugen stock has continued the decline that occurred under the company that it took over, Histogenics. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. In that list, you can even include penny-stock trader. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. OCGN does not even appear to have an apparent reason to exist. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. Type a symbol or company name. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). 2023 InvestorPlace Media, LLC. The average Ocugen stock price for the last 52 weeks is 2.10. For now, the biggest near-term hope for Covaxin may be that Canada or another developed economy will buy the vaccine to share with developing nations. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. It's hard to say for sure. However, I wont be around to find out. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Copyright 2023 InvestorPlace Media, LLC. Please check your download folder. Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. quotes delayed at least 15 minutes, all others at least 20 minutes. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. If Ocugen goes up, you can still profit. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. Thats the thing with these low-priced penny stocks. Nasdaq The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. Making the world smarter, happier, and richer. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. Bharat Biotech has a history of successful vaccine commercialization in South Asia. It means that raising capital will be more difficult going forward. However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. The $25 million private placement executed before the merger brought in much-needed cash. So, what goes wrong? The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. There's still a chance that the vaccine could receive a green light in Canada. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. All rights reserved. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. However, sometimes the optimism isn't justified. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Without NeoCart, that burn likely comes down. Invest better with The Motley Fool. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. You never know when they will suddenly go on a squeeze. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. This requires no immediate effort on your part. The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. 1125 N. Charles St, Baltimore, MD 21201. Keith Speights has no position in any of the stocks mentioned. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Like other life sciences companies involved in Covid-19 vaccine. Start trading Options with Saxo today. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. So far, that merger hasnt worked out for Histogenics former shareholders. Written by The vaccine reportedly has a 78% efficacy rate against COVID-19, significantly lower than leading vaccines granted FDA emergency authorization. Pricing likely would be favorable, given the lack of alternative treatments. Written by This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. For investors new to the story, there are some positives when it comes to OCGN stock. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. Please check your download folder. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. If OCU300 is approved, theres a reasonably large market. Ocugen Inc. is a clinical stage biopharmaceutical company. 1125 N. Charles St, Baltimore, MD 21201. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Histogenics itself highlights the risks involved in small-cap biotech. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. Literally, zero. Ocugen. The Motley Fool recommends Moderna Inc. What Is the Best EV Stock to Buy Now? Do not expect a recovery in Ocugen stock. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. Those lessons will vary between different investors, but I'll point out a major one to keep in mind. The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process. The company is led by CEO and Co-founder, Shankar Musunuri, and entered into the public equity market in 2019 via. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. OCGN Ocugen Inc 155,223 $0.9721 $0.0263 (2.63%) First, the balance sheet is in at least decent shape. The Motley Fool has a disclosure policy. Type a symbol or company name. One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. These symbols will be available throughout the site during your session. This decision isn't surprising, considering that Ocugen previously abandoned the pursuit of an EUA path for the vaccine in adults. Investors who have owned stocks in the last year have generally experienced some big gains. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. *Stock Advisor returns as of June 7, 2021. All rights reserved. Keith Speights for At the time, Ocugen was left for dead. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Investors appear to expect that Bharat's big win for Covaxin in India could translate to success for Ocugen in the U.S. On Dec. 22, Ocugen and Bharat announced a binding letter of intent to jointly develop Covaxin for the U.S. market. CEO Shankar Musunuri stated that he was "pleased to say" that Ocugen was in discussions with the FDA about the data it had submitted for the pediatric EUA. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. Our 3 Top Picks. *Stock Advisor returns as of November 20, 2020. If you missed that action, you missed all the gains. The Motley Fool has no position in any of the stocks mentioned. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. Ocugen hasn't stated yet when a potential late-stage study of Covaxin could start. Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. In this case, shares rallied about four-fold in just a few days. It has no treatments to offer the market. But the allure of the space is that when a company wins, its shareholders win big. Thats not a new problem: a previous Phase 1/2 study, according to the prospectus, was discontinued early due to slow enrollment. The company noted that additional trials may be required as well. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. Unfortunately for longs, OCGN is much closer to the worst of conditions. The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. Sign up below to get this incredible offer! That said, for investors who understand the potential downside, there is an intriguing story here. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 Custom BMW. Theres even room for more lines. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. If they have solid financials, but their trials continually fail, they will likely not succeed. The Motley Fool has no position in any of the stocks mentioned. Almost all the headlines about Ocugen in the past year have been about the companys COVID-19 vaccine candidate. Investors should worry about companies with no revenue even under the best of circumstances. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. (See OCGN stock analysis on TipRanks). Copy and paste multiple symbols separated by spaces. This decision. Thats one of the best rallies weve seen in that amount of time (95 trading sessions, 136 days). The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. The content is intended to be used for informational purposes only. As of this writing, Matt did not hold a position in any of theaforementioned securities. The equity has experienced a continual decline for years. It brings in no revenue. There's a pretty good case to be made that other stocks offer even better prospects for returns with lower risk than Ocugen does. Theres even room for more lines. Unfortunately for investors, the U.S. FDA did not grant Covaxin an Emergency Use Authorization and instead recommended in June that Ocugen opt for a Biologic License Application that will likely require additional Phase 3 testing. The Motley Fool has a disclosure policy. That's right -- they think these 10 stocks are even better buys. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. That's not going to happen now. But it does mean something. Type a symbol or company name. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. The potential synergies of such a union do not seem clear. What Is the Best EV Stock to Buy Now? CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. 1125 N. Charles St, Baltimore, MD 21201. Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. It is very important to do your own analysis before making any investment. The FDA's decision not to issue EUA really wasn't all that surprising, though. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. But realizing value in practice usually is a difficult endeavor. Learn More. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Historical daily share price chart and data for Ocugen since 2023 adjusted for splits. And its at least possible that OCGN could wind up being a winner. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin."
Walks Around Alrewas, Yelling At Someone With Ptsd, What New Restaurants Are Coming To Ocala Florida, Houses For Rent In Sarasota, Fl Under $1000, Articles O